ATE244564T1 - Felbamat-derivate - Google Patents
Felbamat-derivateInfo
- Publication number
- ATE244564T1 ATE244564T1 AT00907199T AT00907199T ATE244564T1 AT E244564 T1 ATE244564 T1 AT E244564T1 AT 00907199 T AT00907199 T AT 00907199T AT 00907199 T AT00907199 T AT 00907199T AT E244564 T1 ATE244564 T1 AT E244564T1
- Authority
- AT
- Austria
- Prior art keywords
- derivatives
- felbamate
- felbamat
- treat
- epilepsy
- Prior art date
Links
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical class NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 abstract 3
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229960003472 felbamate Drugs 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
- C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Iron (AREA)
- Hard Magnetic Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Paper (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11925499P | 1999-02-09 | 1999-02-09 | |
| US13688199P | 1999-06-01 | 1999-06-01 | |
| US13720499P | 1999-06-02 | 1999-06-02 | |
| PCT/US2000/003147 WO2000047202A1 (en) | 1999-02-09 | 2000-02-08 | Felbamate derived compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE244564T1 true ATE244564T1 (de) | 2003-07-15 |
Family
ID=27382271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00907199T ATE244564T1 (de) | 1999-02-09 | 2000-02-08 | Felbamat-derivate |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6538024B1 (de) |
| EP (1) | EP1156798B1 (de) |
| JP (1) | JP2002536409A (de) |
| AT (1) | ATE244564T1 (de) |
| AU (1) | AU771936B2 (de) |
| CA (1) | CA2360258A1 (de) |
| DE (1) | DE60003791T2 (de) |
| DK (1) | DK1156798T3 (de) |
| ES (1) | ES2197078T3 (de) |
| MX (1) | MXPA01007968A (de) |
| NZ (1) | NZ513319A (de) |
| PT (1) | PT1156798E (de) |
| WO (1) | WO2000047202A1 (de) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2407697A1 (en) * | 2000-05-05 | 2001-11-15 | University Of Virginia Patent Foundation | Felbamate derived compounds |
| MXPA03003677A (es) * | 2000-10-25 | 2004-05-04 | Univ Virginia | Compuestos derivados de felbamato sustituidos. |
| US20030166648A1 (en) * | 2002-11-01 | 2003-09-04 | Macdonald Timothy L | Felbamate derived compounds |
| JP4620734B2 (ja) | 2004-06-08 | 2011-01-26 | ランクセス・ドイチュランド・ゲーエムベーハー | 改良された流動性を有するポリアミド成形用組成物 |
| JP4732457B2 (ja) | 2004-06-08 | 2011-07-27 | ランクセス・ドイチュランド・ゲーエムベーハー | 熱可塑性ポリエステルをベースとする改良された流動性を有する成形用組成物 |
| PT1809273E (pt) * | 2004-09-16 | 2010-05-10 | Janssen Pharmaceutica Nv | Utililização de 2-fenil-1,2-etanodiol-(di)carbamatos para tratamento de epileptogénese |
| JP2008538565A (ja) * | 2005-04-21 | 2008-10-30 | メドポイント ヘルスケア インコーポレイテッド | ジカルバメート化合物の合成法およびその作製における中間体 |
| US20070021501A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods of treating epileptogenesis |
| DE102006020984A1 (de) * | 2006-05-04 | 2007-11-08 | Lanxess Deutschland Gmbh | Leichtbauteil in Hybridbauweise |
| DE102007006493A1 (de) * | 2007-02-09 | 2008-08-14 | Lanxess Deutschland Gmbh | Leichtbauteil in Hybridbauweise |
| WO2009129181A1 (en) * | 2008-04-14 | 2009-10-22 | Concert Pharmaceuticals Inc. | Propanediol-dicarbamate derivatives |
| DE102008032205A1 (de) | 2008-07-09 | 2010-01-14 | Lanxess Deutschland Gmbh | Fließverbesserte Thermoplasten |
| DE202008015391U1 (de) | 2008-11-19 | 2010-04-22 | Lanxess Deutschland Gmbh | Türen- und Klappenstrukturen |
| DE202008015399U1 (de) | 2008-11-19 | 2010-04-08 | Lanxess Deutschland Gmbh | Dachstruktur |
| DE202008015395U1 (de) | 2008-11-19 | 2010-04-22 | Lanxess Deutschland Gmbh | Vorderwagenstruktur |
| DE102008058224A1 (de) * | 2008-11-19 | 2010-05-20 | Lanxess Deutschland Gmbh | Leichtbauteil in Hybridbauweise |
| DE202008015397U1 (de) | 2008-11-19 | 2010-04-22 | Lanxess Deutschland Gmbh | Säulenstruktur |
| DE102008058225A1 (de) * | 2008-11-19 | 2010-07-08 | Lanxess Deutschland Gmbh | Leichtbauteil in Hybridbauweise |
| DE202008015401U1 (de) | 2008-11-19 | 2010-04-08 | Lanxess Deutschland Gmbh | Sitzstrukturen |
| DE202008015394U1 (de) | 2008-11-19 | 2010-04-08 | Lanxess Deutschland Gmbh | Längsträgerstruktur |
| DE202008015392U1 (de) | 2008-11-19 | 2010-04-08 | Lanxess Deutschland Gmbh | Pedalstruktur |
| DE202008015396U1 (de) | 2008-11-19 | 2010-04-08 | Lanxess Deutschland Gmbh | Fahrwerkstruktur |
| DE202008015400U1 (de) | 2008-11-19 | 2010-04-08 | Lanxess Deutschland Gmbh | Instrumententafel |
| DE202008015398U1 (de) | 2008-11-19 | 2010-04-08 | Lanxess Deutschland Gmbh | Ölwanne |
| DE102009005763A1 (de) | 2009-01-23 | 2010-07-29 | Lanxess Deutschland Gmbh | Rahmenseitenteil einer Kraftfahrzeug Karosserie |
| ATE522568T1 (de) | 2009-03-27 | 2011-09-15 | Lanxess Deutschland Gmbh | Glühdrahtbeständige polyester |
| DE102009020090A1 (de) | 2009-05-06 | 2010-11-11 | Lanxess Deutschland Gmbh | Reduktion des Einflusses der Wasseraufnahme auf die elektrische Leitfähigkeit von elektrisch leitfähigen Polyamid-Formmassen |
| DE102009034767A1 (de) * | 2009-07-25 | 2011-01-27 | Lanxess Deutschland Gmbh & Co. Kg | Organoblechstrukturbauteil |
| US7964594B1 (en) * | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| UA103272C2 (uk) * | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| DE102010053483A1 (de) | 2010-12-04 | 2012-06-06 | Lanxess Deutschland Gmbh | =N=C=N- enthaltende Verbindung zur Verhinderung des thermischen Abbaus in Schmelzen |
| EP2365028B1 (de) | 2010-03-10 | 2012-10-03 | LANXESS Deutschland GmbH | -N=C=N- enthaltende Verbindungen zur Verhinderung des thermischen Abbaus von Metall-dialkylphosphinat enthaltenden Polyalkylenterephthalaten in der Schmelze |
| CN102190866A (zh) | 2010-03-10 | 2011-09-21 | 朗盛德国有限责任公司 | 用于在熔融物中防止热降解的包括-n=c=n-的化合物 |
| EP2463338B1 (de) | 2010-12-13 | 2013-08-28 | LANXESS Deutschland GmbH | Verfahren zur Optimierung des Kristallisationsverhaltens von Polyester Formmassen |
| EP2465896A1 (de) | 2010-12-14 | 2012-06-20 | LANXESS Deutschland GmbH | Polyester Zusammensetzungen |
| US20140178479A1 (en) * | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| EP2818297B1 (de) | 2013-06-25 | 2016-08-10 | LANXESS Deutschland GmbH | Spritzgießverfahren |
| DE102014000613A1 (de) | 2014-01-18 | 2015-07-23 | Lanxess Deutschland Gmbh | Polyester Zusammensetzungen |
| EP2878625A1 (de) | 2013-11-27 | 2015-06-03 | LANXESS Deutschland GmbH | Polyester Zusammensetzungen |
| IN2014DE03298A (de) | 2013-11-27 | 2015-09-25 | Lanxess Deutschland Gmbh | |
| PL2878628T3 (pl) | 2013-11-27 | 2017-08-31 | Lanxess Deutschland Gmbh | Kompozycje poliestrów |
| DE102014000612A1 (de) | 2014-01-18 | 2015-07-23 | Lanxess Deutschland Gmbh | Polyester Zusammensetzungen |
| EP2878626B1 (de) | 2013-11-27 | 2021-10-27 | LANXESS Deutschland GmbH | Verwendung von polyester-zusammensetzungen |
| HUE047680T2 (hu) | 2013-11-28 | 2020-05-28 | Lanxess Deutschland Gmbh | Poliamid-kompozíciók |
| EP2915841A1 (de) | 2014-03-04 | 2015-09-09 | LANXESS Deutschland GmbH | Polyester Zusammensetzung |
| HUE039596T2 (hu) | 2014-05-05 | 2019-01-28 | Lanxess Deutschland Gmbh | Poliészter vegyületek |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2884444A (en) * | 1956-01-13 | 1959-04-28 | Carter Prod Inc | 2-phenyl-1,3 propane diol dicarbamate |
| US4161582A (en) * | 1976-11-22 | 1979-07-17 | Hoffman-La Roche Inc. | Process to produce oxazinomycin |
| US4384115A (en) * | 1981-12-14 | 1983-05-17 | The Dow Chemical Company | Process for preparing tetrahydro-1,3-oxazin-2-ones |
| US4868327A (en) | 1987-06-03 | 1989-09-19 | Carter-Wallace, Inc. | Synthesis of 2-phenyl-1,3-propanediol |
| US4978680A (en) | 1989-09-26 | 1990-12-18 | Carter-Wallace, Inc. | Method for the prevention and control of epileptic seizure |
| US5082861A (en) | 1989-09-26 | 1992-01-21 | Carter-Wallace, Inc. | Method for the prevention and control of epileptic seizure associated with complex partial seizures |
| US5292772A (en) | 1989-09-26 | 1994-03-08 | Carter-Wallace, Inc. | Method for the prevention and control of epileptic seizure associated with Lennox-Gastaut syndrome |
| US5055489A (en) | 1990-05-04 | 1991-10-08 | Carter-Wallace, Inc. | Method for the prevention and control of hypoxic damage resulting from cerebral ischemic events |
| IL107002A0 (en) * | 1992-09-18 | 1993-12-28 | Avondale Chem Corp | Process for preparing felbamate and intermediates thereof |
| US5462966A (en) | 1993-10-15 | 1995-10-31 | Carter-Wallace Inc. | Methods for the prevention and control of cellular damage resulting from coronary artery occlusion-reperfusion |
| US5492930A (en) * | 1994-04-25 | 1996-02-20 | Schering Corporation | Method and formulation for treating CNS disorders |
| US5728728A (en) | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
-
2000
- 2000-02-08 JP JP2000598154A patent/JP2002536409A/ja active Pending
- 2000-02-08 CA CA002360258A patent/CA2360258A1/en not_active Abandoned
- 2000-02-08 DK DK00907199T patent/DK1156798T3/da active
- 2000-02-08 NZ NZ513319A patent/NZ513319A/en unknown
- 2000-02-08 WO PCT/US2000/003147 patent/WO2000047202A1/en not_active Ceased
- 2000-02-08 DE DE60003791T patent/DE60003791T2/de not_active Expired - Fee Related
- 2000-02-08 AU AU28734/00A patent/AU771936B2/en not_active Ceased
- 2000-02-08 MX MXPA01007968A patent/MXPA01007968A/es not_active IP Right Cessation
- 2000-02-08 EP EP00907199A patent/EP1156798B1/de not_active Expired - Lifetime
- 2000-02-08 AT AT00907199T patent/ATE244564T1/de not_active IP Right Cessation
- 2000-02-08 PT PT00907199T patent/PT1156798E/pt unknown
- 2000-02-08 ES ES00907199T patent/ES2197078T3/es not_active Expired - Lifetime
-
2001
- 2001-08-09 US US09/925,224 patent/US6538024B1/en not_active Expired - Fee Related
- 2001-12-17 US US10/023,059 patent/US6599935B2/en not_active Expired - Fee Related
-
2003
- 2003-06-06 US US10/456,117 patent/US6759402B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60003791D1 (de) | 2003-08-14 |
| JP2002536409A (ja) | 2002-10-29 |
| EP1156798B1 (de) | 2003-07-09 |
| MXPA01007968A (es) | 2003-07-14 |
| PT1156798E (pt) | 2003-11-28 |
| CA2360258A1 (en) | 2000-08-17 |
| AU2873400A (en) | 2000-08-29 |
| US6599935B2 (en) | 2003-07-29 |
| US6538024B1 (en) | 2003-03-25 |
| EP1156798A4 (de) | 2002-07-17 |
| AU771936B2 (en) | 2004-04-08 |
| US20020156070A1 (en) | 2002-10-24 |
| ES2197078T3 (es) | 2004-01-01 |
| US6759402B2 (en) | 2004-07-06 |
| US20030229086A1 (en) | 2003-12-11 |
| DE60003791T2 (de) | 2004-02-05 |
| NZ513319A (en) | 2003-08-29 |
| WO2000047202A1 (en) | 2000-08-17 |
| DK1156798T3 (da) | 2003-11-03 |
| EP1156798A1 (de) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60003791D1 (de) | Felbamat-derivate | |
| TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
| ECSP003610A (es) | Pirimidina-2,4,6 trionas inhibidores de metaloproteinas | |
| TR199901904T2 (xx) | 3-piridil enantiyomerleri ve bunlar�n analjezik olarak kullan�lmas�. | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| ES2119124T3 (es) | Bencimidazoles utiles para el tratamiento de trastornos del sistema nervioso. | |
| PA8481301A1 (es) | Derivados de 4,4-biarilpiperidina | |
| TR200401545T4 (tr) | NOSS inhibitörü ilaçların amalatı için ikame imidazo [1,2-a]piridin-,-pirimidin- ve-pirazin-3-amin-türevlerinin kullanımı | |
| ATE324444T1 (de) | Tek-antagonisten | |
| ATE277929T1 (de) | Immunsuppressive wirkungen von pteridinderivaten | |
| DE60144277D1 (de) | Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta | |
| UY26130A1 (es) | Compuestos para tratar la obesidad | |
| ES2168359T3 (es) | Acido micofenolico 6-sustituido y derivados con actividad inmunosupresora. | |
| MXPA04006184A (es) | Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c. | |
| BR0212617A (pt) | Compostos de pirazolila substituìdo para o tratamento de inflamação | |
| MY119375A (en) | Treatment of tinnitus using neuroprotective agents | |
| CR6824A (es) | Derivados de arilmetilamina para uso como inhibidores de triptasa | |
| DK1032556T3 (da) | Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder | |
| DE60016181D1 (de) | C-16 ungesätigte fp-selektive prostaglandin analoge | |
| ES2064119T3 (es) | Nuevos derivados de aminobenzosultam como inhibidores de la lipoxigenasa. | |
| DE60026491D1 (de) | Melagatran zur behandlung von entzündungen | |
| EE05241B1 (et) | Distamtsiini a-halogenoakrlolderivaadi kasutamine | |
| ECSP003590A (es) | Compuestos calcioliticos | |
| YU58601A (sh) | Derivati fenilalaninola | |
| ES2118248T3 (es) | Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1156798 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |